Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.
Rituximab (marketed as Rituxan), Information
Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Information for healthcare professionals: Rituximab
Current and future immunotherapy targets in autoimmune neurology.
The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies.
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
NOVANTRONE. mitoXANTRONE for injection concentrate
Ampyra (dalfampridine)
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Chemotactic Cytokines: Gordon Research Conference on Molecular and Cellular Mechanisms in Health and Disease

Pages